Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anandaroop Dasgupta

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 20, 2011
Effect of bar-code-assisted medication administration on nurses' activities in an intensive care unit: a time-motion studyNilanjana Dwibedi, Sujit S Sansgiry, Craig P Frost, et al.
Brain and Behavior|January 6, 2021
How well do clinical and demographic characteristics predict Patient Health Questionnaire-9 scores among patients with treatment-resistant major depressive disorder in a real-world setting?Jennifer Voelker, Kruti Joshi, Ella Daly, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast CancerHope S Rugo, Aditya Bardia, Peter Schmid, et al.
Advances in Therapy|November 19, 2020
Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myelomaJianming He, Luke Schmerold, Rian Van Rampelbergh, et al.
Nature Medicine|October 1, 2024
Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trialBinghe Xu, Shusen Wang, Min Yan, et al.
JCO Oncology Practice|June 25, 2025
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Hope S Rugo, Mina S Sedrak, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 20, 2011
Effect of bar-code-assisted medication administration on nurses' activities in an intensive care unit: a time-motion studyNilanjana Dwibedi, Sujit S Sansgiry, Craig P Frost, et al.
Brain and Behavior|January 6, 2021
How well do clinical and demographic characteristics predict Patient Health Questionnaire-9 scores among patients with treatment-resistant major depressive disorder in a real-world setting?Jennifer Voelker, Kruti Joshi, Ella Daly, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast CancerHope S Rugo, Aditya Bardia, Peter Schmid, et al.
Advances in Therapy|November 19, 2020
Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myelomaJianming He, Luke Schmerold, Rian Van Rampelbergh, et al.
Nature Medicine|October 1, 2024
Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trialBinghe Xu, Shusen Wang, Min Yan, et al.
JCO Oncology Practice|June 25, 2025
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Hope S Rugo, Mina S Sedrak, et al.
Pageof 2